All Stories

  1. In Memoriam: Robert Emmons Kissling (1923–2013)
  2. Coltiviruses
  3. A manifesto for planetary health
  4. Preclinical and Clinical Development of a YFV 17 D-Based Chimeric Vaccine against West Nile Virus
  5. 17D Yellow Fever Virus Vaccine
  6. Vaccines against diseases transmitted from animals to humans: A one health paradigm
  7. Fever versus fever: The role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus
  8. Adaptation of yellow fever virus 17D to Vero cells is associated with mutations in structural and non-structural protein genes
  9. Yellow fever vaccine
  10. Review of the risks and benefits of yellow fever vaccination including some new analyses
  11. Full Genomic Sequence of the Prototype Strain (M64) of Rio Bravo Virus
  12. Cationic liposome–DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice
  13. Yellow Fever Vaccine Seroconversion in Travelers
  14. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model
  15. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever
  16. Yellow fever
  17. An Inactivated Cell-Culture Vaccine against Yellow Fever
  18. Development of Antigen-Specific Memory CD8+ T Cells Following Live-Attenuated Chimeric West Nile Virus Vaccination
  19. Yellow Fever
  20. Yellow Fever Vaccines: The Success of Empiricism, Pitfalls of Application, and Transition to Molecular Vaccinology
  21. Classical Live Viral Vaccines
  22. Recombinant, Chimeric, Live, Attenuated Vaccines Against Flaviviruses and Alphaviruses
  23. Architectural options and challenges for next generation optical access
  24. A multi-actor analysis of the QoE environment
  25. Economical analysis of experience-optimized service delivery
  26. Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity
  27. Suspected Yellow Fever Vaccine-Associated Viscerotropic Adverse Events (1973 and 1978), United States
  28. The Convergence of Human and Animal Medicine
  29. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses
  30. One Health Perspective
  31. Yellow Fever
  32. Viscerotropic disease following yellow fever vaccination in Peru
  33. Evaluation of Chimeric Japanese Encephalitis and Dengue Viruses for Use in Diagnostic Plaque Reduction Neutralization Tests
  34. Possible autoimmune reactions following smallpox vaccination: The biologic false positive test for syphilis
  35. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax® in healthy vaccinia-naive adults
  36. Yellow Fever
  37. 'ONE HEALTH' and parasitology
  38. 91. Stabilization of live biologicals at ambient temperatures using preservation by vaporization
  39. Use of a Surrogate Chimeric Virus To Detect West Nile Virus-Neutralizing Antibodies in Avian and Equine Sera
  40. Safety of flavivirus chimeric vaccines: Answer to Ishikawa et al. [Vaccine 26 (22) (2008) 2772–2781]
  41. Executive summary of the AVMA One Health Initiative Task Force report
  42. Treatment of yellow fever
  43. Teaching “One Medicine, One Health”
  44. Improving vaccine coverage in Africa
  45. Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge
  46. Dengue and Yellow Fever — Challenges for the Development and Use of Vaccines
  47. Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences
  48. Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE)
  49. A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus
  50. 17D yellow fever vaccines: New insights
  51. Viral vectors for malaria vaccine development
  52. Coltiviruses
  53. Correction for Monath et al., A live, attenuated recombinant West Nile virus vaccine
  54. A live, attenuated recombinant West Nile virus vaccine
  55. Lack of Transmission of Vaccinia Virus
  56. Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All
  57. Yellow Fever
  58. Flow‐Cytometric Detection of Vaccinia‐Induced Memory Effector CD4 + , CD8 + , and γδTCR + T Cells Capable of Antigen‐Specific Expansion and Effector Functions
  59. New developments in flavivirus vaccines with special attention to yellow fever
  60. Yellow Fever 17D Vaccine Safety and Immunogenicity in the Elderly
  61. Interview with Thomas P. Monath, M.D.
  62. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: Infant mice provide an accurate surrogate for the test in monkeys
  63. Yellow fever vaccine
  64. Yellow fever
  65. Virology Division News
  66. A novel, cell culture-derived smallpox vaccine in vaccinia-naïve adults
  67. Cutaneous Delivery of a Live, Attenuated Chimeric Flavivirus Vaccines against Japanese Encephalitis (ChimeriVaxTM-JE) in Non-Human Primates
  68. Recombination and flavivirus vaccines: a commentary
  69. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea
  70. Exercise-Induced Serum Enzyme Elevations Confounding the Evaluation of Investigational Drug Toxicity: Report of Two Cases in a Vaccine Trial
  71. ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy
  72. New Concepts for Vaccines1
  73. Specific Immunoglobulin A Antibodies in Maternal Milk and Delayed Helicobacter pylori Colonization in Gambian Infants
  74. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) – a second-generation smallpox vaccine for biological defense
  75. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) – a second-generation smallpox vaccine for biological defense
  76. A Single Amino Acid Substitution in the Envelope Protein of Chimeric Yellow Fever-Dengue 1 Vaccine Virus Reduces Neurovirulence for Suckling Mice and Viremia/Viscerotropism for Monkeys
  77. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax™-JE experimental vaccine
  78. Chimeric Vaccines Against Japanese Encephalitis, Dengue, and West Nile
  79. High Fidelity of Yellow Fever Virus RNA Polymerase
  80. High rates of recurrence and of transient reinfections of Helicobacter pylori in a population with high prevalence of infection
  81. Helicobacter pylori Reinfection Is Common in Peruvian Adults after Antibiotic Eradication Therapy
  82. Chimeric Live, Attenuated Vaccine against Japanese Encephalitis (ChimeriVax‐JE): Phase 2 Clinical Trials for Safety and Immunogenicity, Effect of Vaccine Dose and Schedule, and Memory Response to Challenge with Inactivated Japanese Encephalitis Antigen
  83. Growth characteristics of the veterinary vaccine candidate ChimeriVax™‐West Nile (WN) virus in Aedes and Culex mosquitoes
  84. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine
  85. THOMAS MONATH PROFILE: Riding the Biodefense Wave
  86. Development of a Novel Vaccinia‐Neutralization Assay Based on Reporter‐Gene Expression
  87. Traditional and novel approaches to flavivirus vaccines
  88. Clostridium difficile Vaccine and Serum Immunoglobulin G Antibody Response to Toxin A
  89. Coltiviruses
  90. Pathogenesis and Pathophysiology of Yellow Fever
  91. Epidemiology and ecology of yellow fever virus
  92. Chimeric Flaviviruses: Novel Vaccines against Dengue Fever, Tick-borne Encephalitis, and Japanese Encephalitis
  93. Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori
  94. Efficacy of Killed Virus Vaccine, Live Attenuated Chimeric Virus Vaccine, and Passive Immunization for Prevention of West Nile virus Encephalitis in Hamster Model
  95. Attenuated Salmonella enterica Serovar Typhi Expressing Urease Effectively Immunizes Mice against Helicobacter pylori Challenge as Part of a Heterologous Mucosal Priming-Parenteral Boosting Vaccination Regimen
  96. Viremia and Immunogenicity in Nonhuman Primates of a Tetravalent Yellow Fever–Dengue Chimeric Vaccine: Genetic Reconstructions, Dose Adjustment, and Antibody Responses against Wild-type Dengue Virus Isolates
  97. Prevention of Yellow Fever in Persons Traveling to the Tropics
  98. Single Mutation in the Flavivirus Envelope Protein Hinge Region Increases Neurovirulence for Mice and Monkeys but Decreases Viscerotropism for Monkeys: Relevance to Development and Safety Testing of Live, Attenuated Vaccines
  99. Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing
  100. Clinical proof of principle for ChimeriVax™: recombinant live, attenuated vaccines against flavivirus infections
  101. Japanese Encephalitis Vaccines: Current Vaccines and Future Prospects
  102. Prospects for Development of a Vaccine against the West Nile Virus
  103. Phenotypic and Molecular Analyses of Yellow Fever 17DD Vaccine Viruses Associated with Serious Adverse Events in Brazil
  104. Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent
  105. Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine
  106. Yellow fever: an update
  107. Yellow fever vector live-virus vaccines: West Nile virus vaccine development
  108. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases
  109. Posttreatment Follow-Up of Helicobacter pylori Infection Using a Stool Antigen Immunoassay
  110. Yellow Fever
  111. West Nile Virus Vaccine.
  112. Formulations of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by the systemic route in mice Optimal prophylactic combinations are different from therapeutic ones
  113. Safety and Immunogenicity of Increasing Doses of aClostridium difficile Toxoid Vaccine Administered to Healthy Adults
  114. Molecular Basis for Attenuation of Neurovirulence of a Yellow Fever Virus/Japanese Encephalitis Virus Chimera Vaccine (ChimeriVax-JE)
  115. Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates
  116. Parenteral Adjuvant Activities of Escherichia coli Heat-Labile Toxin and Its B Subunit for Immunization of Mice against Gastric Helicobacter pyloriInfection
  117. Low dose E. coli enterotoxin for urease-based oral immunization against H. pylori in healthy volunteers: Can it be safe and effective
  118. Chimeric Yellow Fever Virus 17D-Japanese Encephalitis Virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing in Rhesus Monkeys
  119. Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori
  120. Facing up to re-emergence of urban yellow fe ver
  121. Immunogenicity, Genetic Stability, and Protective Efficacy of a Recombinant, Chimeric Yellow Fever-Japanese Encephalitis Virus (ChimeriVax-JE) as a Live, Attenuated Vaccine Candidate against Japanese Encephalitis
  122. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax™) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-huma...
  123. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori–infected adults
  124. Effects of humanization by variable domain resurfacing on the antiviral activity of a single-chain antibody against respiratory syncytial virus
  125. Ecology of Marburg and Ebola Viruses: Speculations and Directions for Future Research
  126. Immunization of Mice with Urease Vaccine Affords Protection against Helicobacter pylori Infection in the Absence of Antibodies and Is Mediated by MHC Class II–restricted Responses
  127. Does Restricted Distribution Limit Access and Coverage of Yellow Fever Vaccine in the United States?
  128. BIOLOGICAL WARFARE:Strengthening the Biological Weapons Convention
  129. Specific anti-H. pyloriurease IgA in human Breastmilk and delayedH. pyloricolonisation in Gambian infants.
  130. Vaccine development against infection with Helicobacter pylori
  131. Early indicators in acute dengue infection
  132. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting
  133. Gastritis in urease-immunized mice after Helicobacter felis challenge may be due to residual bacteria
  134. Physicians identify Clostridium difficile colitis as a serious problem in need of new immune therapies
  135. Cloning, expression and functional activities of a single chain antibody fragment directed to fusion protein of respiratory syncytial virus
  136. Immunogenicity and safety of recombinantHelicobacter pylori urease in a nonhuman primate
  137. Intranasal Monoclonal IgA Antibody to Respiratory Syncytial Virus Protects Rhesus Monkeys against Upper and Lower Respiratory Tract Infection
  138. Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets
  139. Antigenicity of amino-acid sequences from Clostridium difficile toxin B
  140. Oral Immunization with Recombinant Helicobacter pylori Urease Induces Secretory IgA Antibodies and Protects Mice from Challenge with Helicobacter felis
  141. Adaptation of bluetongue virus in mosquito cells results in overexpression of NS3 proteins and release of virus particles
  142. Specific amplification by PCR of rearranged genomic variable regions of immunoglobulin genes from mouse hybridoma cells.
  143. Prophylactic therapy of respiratory syncytial virus (RSV) infection of rhesus monkeys with monoclonal IgA antibody to RSV
  144. Vector‐borne Emergent Disease
  145. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice.
  146. Yellow fever and dengue—the interactions of virus, vector and host in the re-emergence of epidemic disease
  147. Dengue: the risk to developed and developing countries.
  148. Analysis of a Yellow Fever Virus Isolated from a Fatal Case of Vaccine-Associated Human Encephalitis
  149. Geographic distribution and evolution of yellow fever viruses based on direct sequencing of genomic cDNA fragments
  150. Yellow fever vaccination and pregnancy: a four-year prospective study
  151. Antiviral (RNA) Activity of Selected Amaryllidaceae Isoquinoline Constituents and Synthesis of Related Substances
  152. Synthesis and antiviral evaluation of N-carboxamidine-substituted analogs of 1-.beta.-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride.
  153. Obituary Joel McKeith Dalrymple (1939–1992)
  154. The Challenge: Biotechnology Transfer to Public Health. Examples from Arbovirology
  155. Activity of Selected Amaryllidaceae Constituents and Related Synthetic Substances Against Medically Important RNA Viruses
  156. Antiviral (RNA) evaluation of a series of substituted tyrosines
  157. Ebola infected SCID mice as a model for drug evaluation
  158. Inhibition of ebola virus replication in vitro and in a SCID mouse model by S-adenosylhomocysteine hydrolase inhibitors
  159. Ribavirin, interferon, and antibody approaches to prophylaxis and therapy for viral hemorrhagic fevers
  160. Imported Lassa Fever — Reexamining the Algorithms
  161. Attenuation of wild-type yellow fever virus by passage in HeLa cells
  162. Evaluation of the Potency and Safety of Inactivated Japanese Encephalitis Vaccine in US Inhabitants
  163. The Molecular Epidemiology of Dengue Viruses
  164. Potential for Insect Transmission of HIV: Experimental Exposure of Cimex hemipterus and Toxorhynchites amboinensis to Human Immunodeficiency Virus
  165. Genetic variation and microevolution of dengue 2 virus in Southeast Asia
  166. Urban yellow fever epidemic in western Nigeria, 1987
  167. Japanese Encephalitis — A Plague of the Orient
  168. Dengue 2 Virus Envelope Protein Expressed by a Recombinant Vaccinia Virus Fails to Protect Monkeys against Dengue
  169. "YELLOWFEVER" IN EASTERN NIGERIA
  170. EPIDEMIC YELLOW FEVER IN EASTERN NIGERIA, 1986
  171. Togaviridae and Flaviviridae: The Alphavirases and Flaviviruses
  172. EPIZOOTIC VESICULAR STOMATITIS IN COLORADO, 1982: SOME OBSERVATIONS ON THE POSSIBLE ROLE OF WILDLIFE POPULATIONS IN AN ENZOOTIC MAINTENANCE CYCLE
  173. Lassa Fever--New Issues Raised by Field Studies in West Africa
  174. Type B hepatitis and yellow fever infections in West Africa
  175. Yellow Fever: A Medically Neglected Disease. Report on a Seminar
  176. Genetic and Epidemiological Studies of Dengue Type 2 Viruses by Hybridization Using Synthetic Deoxyoligonucleotides as Probes
  177. Geographic classification of dengue-2 virus strains by antigen signature analysis
  178. Aedes albopictus, an Exotic Mosquito Vector in the United States
  179. Multisite Monoclonal Immunoassay for Dengue Viruses: Detection of Viraemic Human Sera and Interference by Heterologous Antibody
  180. Pathobiology of the Flaviviruses
  181. Genetic Heterogeneity of Yellow Fever Virus Strains from Africa and the Americas
  182. Intérêt du titrage par elisa des IgM spécifiques pour le diagnostic et la surveillance de la circulation selvatique des flavivirus en afrique
  183. LeDantec Virus: Identification as a Rhabdovirus Associated with Human Infection and Formation of a New Serogroup
  184. Comparaison de différentes techniquespour la détection du virus de la fièvre jaune dans les prélèvements humains et les lots de moustiques: Intérêt d'une méthode rapide de diagnostic par ELISA
  185. Sindbis virus isolations from Saudi Arabian mosquitoes
  186. Impact of Arthropod-Borne Virus Diseases on Africa and the Middle East
  187. Genetic variation among dengue 2 viruses of different geographic origin
  188. Ontogeny of Yellow Fever 17D Vaccine: RNA Oligonucleotide Fingerprint and Monoclonal Antibody Analyses of Vaccines Produced World-wide
  189. Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein
  190. From the Centers for Disease Control
  191. Genetic heterogeneity among Saint Louis encephalitis virus isolates of different geographic origin
  192. Indirect fluorescent antibody test for the diagnosis of yellow fever
  193. VARIATION AMONG STRAINS OF ST. LOUIS ENCEPHALITIS VIRUS: BASIS FOR A GENETIC, PATHOGENETIC, AND EPIDEMIOLOGIC CLASSIFICATION
  194. Studies of glucose metabolism in rhesus monkeys after venezuelan equine encephalitis virus infection
  195. Viruses isolated from reptiles: Identification of three new members of the familyRhabdoviridae
  196. Necrotizing Myocarditis in Mice Infected with Western Equine Encephalitis Virus: Clinical, Electrocardiographic, and Histopathologic Correlations
  197. St. Louis Encephalitis in Memphis-Shelby County, Tennessee, 1975
  198. Dengue virus infections in Nigeria: a survey for antibodies in monkeys and humans
  199. Lassa Virus Isolation from Mastomys natalensis Rodents during an Epidemic in Sierra Leone
  200. Experimental Studies of Rhesus Monkeys Infected with Epizootic and Enzootic Subtypes of Venezuelan Equine Encephalitis Virus
  201. Arbovirus studies in nupeko forest, a possible natural focus of yellow fever virus in Nigeria II. Entomological investigations and viruses isolated
  202. Bwamba virus infection: A sero-survey of veterbrates in five ecological zones in Nigeria
  203. Arbovirus studies in nupeko forest, a possible natural focus of yellow fever virus in Nigeria I. Description of the area and serological survey of humans and other vertebrate hosts
  204. Lassa fever in Britain: an imported case.
  205. Characterization of viruses (Witwatersrand and Germiston) isolated from mosquitoes and rodents collected near Lunyo Forest, Uganda, in 1968
  206. Effects of Thorotrast on Humoral Antibody, Viral Multiplication, and Interferon during Infection with St. Louis Encephalitis Virus in Mice